Azenta Q1 rev $154M (-13% YoY), GAAP EPS ($0.28), non-GAAP $0.02; reaffirms FY24 guide

Azenta, Inc.

2024-Q1 EPS reported -$0.28 revenue$154,317,000

Revenue $154M, down 13% YoY; organic revenue -15%; combined Sample Mgmt & Multiomics grew 2% organic.
GAAP diluted EPS from continuing ops ($0.28) vs ($0.15) prior year; non-GAAP diluted EPS $0.02 vs $0.12.
B Medical revenue $13M, down 70% YoY (timing of orders); Sample Mgmt Solutions up 5%, Multiomics up 3%.
FY2024 guidance reaffirmed: total revenue $696-$718M, non-GAAP EPS $0.19-$0.29, adj EBITDA margin +300bps.
Repurchased 2.3M shares for $113M in Q1; plans additional $500M in FY2024 to complete $1.5B authorization.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Azenta, Inc. reported the first quarter ended December 31, 2023 results: revenue $ 154, net income $ (0.28), EPS $(0.28) per diluted share. Guidance reaffirmed.

Period: the first quarter ended December 31, 2023
Revenue: $ 154
Net income: $ (0.28)
EPS: $(0.28) per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

in millions, except per share data December 31, September 30, December 31, Change 2023 2023 2022 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 154 $ 172 $ 178 (10) % (13) % Organic growth (15) % Sample Management Solutions $ 79 $ 82 $ 75 (3) % 5 % Multiomics $ 63 $ 61 $ 61 3

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Azenta, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-000860

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.